BRISTOL MYERS SQUIBB CO

BMY 10-Q · Q2 2025
API behind this page

BMY Q2 2025 request

Playground key active
Request URL /api/financials?ticker=BMY&year=2025&quarter=2
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q2 2025 Q2 2024 YoY
Revenue 12,269 12,201 +0.6%
Show Product Lines breakouts
Abecma 87 95 -8.4%
Abraxane 105 231 -54.5%
Alliance and other revenues 360 276 +30.4%
Alliance revenues 119 116 +2.6%
Alliance revenues · Collaborative Arrangement 119 116 +2.6%
Breyanzi 344 153 +124.8%
Camzyos 260 139 +87.1%
Cobenfy 35 — —
Eliquis 3,680 3,416 +7.7%
Gross product sales 22,181 20,780 +6.7%
Growth Portfolio 6,596 5,596 +17.9%
Krazati 48 32 +50.0%
Legacy Portfolio 5,673 6,605 -14.1%
Net product sales 11,909 11,925 -0.1%
Net product sales · Collaborative Arrangement 3,720 3,470 +7.2%
Opdivo 2,560 2,387 +7.2%
Opdivo Qvantig 30 — —
Opdualag 284 235 +20.9%
Orencia 963 948 +1.6%
Other Growth products 470 348 +35.1%
Other Legacy products 223 222 +0.5%
Other revenues 241 160 +50.6%
Pomalyst/Imnovid 708 959 -26.2%
Reblozyl 568 425 +33.6%
Revlimid 838 1,353 -38.1%
Sotyktu 70 53 +32.1%
Sprycel 120 424 -71.7%
Yervoy 728 630 +15.6%
Zeposia 150 151 -0.7%
Show Geography breakouts
Non Us 3,481 3,224 +8.0%
Other 270 176 +53.4%
US 8,519 8,801 -3.2%
Show Type Of Arrangement breakouts
Collaborative Arrangement 3,840 3,586 +7.1%
Cost of Revenue 3,372 3,267 +3.2%
Show Type Of Arrangement breakouts
Collaborative Arrangement 1,827 1,692 +8.0%
Selling, General & Administrative 1,713 1,928 -11.2%
Show Type Of Arrangement breakouts
Collaborative Arrangement 68 65 +4.6%
Research & Development 2,580 2,899 -11.0%
Show Nature Of Expense breakouts
Drug Development 1,095 1,096 -0.1%
Other 1,195 1,467 -18.5%
Research 291 336 -13.4%
Acquired I P R D 1,508 132 +1042.4%
Amortizationof Acquired Intangible Assets 830 2,416 -65.6%
Other Non-Operating Income (Expense) 494 273 +81.0%
Show Type Of Arrangement breakouts
Collaborative Arrangement -10 -102 +90.2%
Total Costs & Expenses 10,496 10,915 -3.8%
Income Before Taxes 1,773 1,286 +37.9%
Income Tax Expense (Benefit) 460 -398 +215.6%
Net Income 1,313 1,684 -22.0%
Show Equity Components breakouts
Noncontrolling Interest 2 4 -50.0%
Retained Earnings 1,310 1,680 -22.0%
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 2 4 -50.0%
Net Income 1,310 1,680 -22.0%
EPS (Basic) 0.64 0.83 -22.9%
EPS (Diluted) 0.64 0.83 -22.9%
Interest Expense 485 521 -6.9%
Interest Income -139 -87 -59.8%
Comprehensive Income 1,181 1,624 -27.3%
Wtd Avg Shares (Basic) 2,035 2,027 +0.4%
Wtd Avg Shares (Diluted) 2,038 2,029 +0.4%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) — — —
Show Equity Components breakouts
Accumulated Other Comprehensive Income -181 72 -351.4%
Income Loss From Equity Method Investments 37 -28 +232.1%
Gain Loss On Investments 22 -107 +120.6%

Balance Sheet

Balance Sheet
Metric Q2 2025 Q2 2024 YoY
Current Assets
Cash & Cash Equivalents 12,599 6,293 +100.2%
Available For Sale Securities Debt Securities Current 1,004 360 +178.9%
Receivables Net Current 11,415 11,423 -0.1%
Show Type Of Arrangement breakouts
Collaborative Arrangement 218 290 -24.8%
Inventory 2,737 3,077 -11.0%
Other Assets Current 5,466 5,737 -4.7%
Total Current Assets 33,222 26,890 +23.5%
Accounts Receivable 9,711 9,746 -0.4%
Non-Current Assets
Property, Plant & Equipment 7,373 6,845 +7.7%
Goodwill 21,776 — —
Deferred Tax Assets 4,647 3,323 +39.8%
Available For Sale Securities Debt Securities Noncurrent 346 357 -3.1%
Other Non-Current Assets 5,936 6,071 -2.2%
Total Assets 94,676 94,646 0.0%
Operating Lease Right-of-Use Assets 1,276 1,316 -3.0%
Other Assets
Intangible Assets Net Excluding Goodwill 21,378 29,428 -27.4%
Show Finite Lived Intangible Assets By Major Class breakouts
Acquired marketed product rights 11,773 18,747 -37.2%
Computer Software Intangible Asset 380 436 -12.8%
Technology Based Intangible Assets 1,540 1,870 -17.6%
Show Indefinite Lived Intangible Assets By Major Class breakouts
In Process Research And Development 7,685 8,375 -8.2%
Current Liabilities
Debt Current 4,715 3,531 +33.5%
Accounts Payable 5,427 3,751 +44.7%
Show Type Of Arrangement breakouts
Collaborative Arrangement 3,306 1,627 +103.2%
Other Liabilities Current 17,386 15,983 +8.8%
Total Current Liabilities 27,528 23,265 +18.3%
Current Portion of Long-Term Debt 4,475 3,092 +44.7%
Non-Current Liabilities
Deferred Tax Liabilities 247 461 -46.4%
Long-Term Debt 44,470 48,858 -9.0%
Other Non-Current Liabilities 4,942 4,993 -1.0%
Total Liabilities 77,187 77,577 -0.5%
Long-Term Debt 48,945 51,950 -5.8%
Operating Lease Liabilities 1,550 1,438 +7.8%
Accrued Income Taxes Noncurrent 1,438 1,783 -19.3%
Stockholders' Equity
Common Stock Value Outstanding 292 292 0.0%
Additional Paid-In Capital 46,134 45,766 +0.8%
Accumulated Other Comprehensive Income -1,554 -1,456 -6.7%
Retained Earnings 16,154 16,103 +0.3%
Treasury Stock Common Value -43,590 — —
Total Stockholders' Equity 17,435 — —
Minority Interest 54 54 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 17,489 — —
Show Equity Components breakouts
Accumulated Other Comprehensive Income -1,554 -1,456 -6.7%
Additional Paid In Capital 46,134 45,766 +0.8%
Common Stock 292 292 0.0%
Noncontrolling Interest 54 54 0.0%
Retained Earnings 16,154 16,103 +0.3%
Treasury Stock Common -43,590 -43,690 +0.2%
Total Liabilities & Equity 94,676 94,646 0.0%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q2 2025 YTD Q2 2024 YoY
Operating Activities
Depreciation & Amortization 2,023 5,128 -60.5%
Deferred Income Taxes -214 -1,042 +79.5%
Stock-Based Compensation 281 258 +8.9%
Impairment Of Long Lived Assets To Be Disposed Of 318 871 -63.5%
Divestituregainsandroyalties -585 -550 -6.4%
Equity Method Investment Realized Gain Loss On Disposal 100 -209 +147.8%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 336 — —
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 (Q) — — —
Show Contingent Consideration By Type breakouts
Contingent value rights 336 — —
Other Non-Cash Items -2 20 -110.0%
Increase Decrease In Receivables -469 -540 +13.1%
Change in Inventory -165 -443 +62.8%
Change in Accounts Payable -72 41 -275.6%
Increase Decrease In Other Accrued Liabilities 254 70 +262.9%
Increase Decrease In Accrued Income Taxes Payable -567 -1,033 +45.1%
Increase Decrease In Other Operating Capital Net -837 -268 -212.3%
Net Cash from Operations 5,871 5,160 +13.8%
Investing Activities
Proceeds From Sale And Maturity Of Available For Sale Securities 744 822 -9.5%
Payments To Acquire Marketable Securities -1,257 -358 -251.1%
Proceeds From Sale Of Equity Securities Fv Ni 12 60 -80.0%
Capital Expenditures -621 -546 -13.7%
Divestitureandotherproceeds 513 511 +0.4%
Payments To Acquire Businesses Net Of Cash Acquired -363 -21,426 +98.3%
Net Cash from Investing -972 -20,937 +95.4%
Financing Activities
Proceeds From Other Short Term Debt 426 409 +4.2%
Repayments Of Long Term Debt -643 -395 -62.8%
Payments Of Dividends -2,520 -2,429 -3.7%
Payments For Proceeds From Stock Option Exercises And Other Adjustments -92 -103 +10.7%
Net Cash from Financing -2,829 10,621 -126.6%
Supplemental
Income Taxes Paid 1.8 2.1 -14.3%
Interest Paid 1 735 -99.9%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 194 -67 +389.6%
Net Change in Cash 2,264 -5,223 +143.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 12,611 6,296 +100.3%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key